The reiteration of a Buy rating and maintenance of a $28 price target by a reputable analyst like Edward White from HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short term impact on Lumos Pharma's stock price. Analyst ratings, especially from well-regarded firms, often influence investor perception and can lead to stock price movements.